Skip to main content

Table 3 List of detected positron emission tomography agents

From: Clinical trials involving positron emission tomography and prostate cancer: an analysis of the database

Positron Emission Tomography Agent as Stated in Radionuclid IUPAC name of the carrier or other relevant source Number of trials
Acetate (11C)a Acetate 22
Choline (11C)a 2-Hydroxy-N,N,N-trimethylethan-1-aminium 16
Choline (18F)a 2-Hydroxy-N,N,N-trimethylethan-1-aminium 37
Choline NOSa 2-Hydroxy-N,N,N-trimethylethan-1-aminium 7
Citrate (68Ga) 2-Hydroxypropane-1,2,3-tricarboxylic acid 1
DFO-huJ591 (89Zr) Recombinant humanized monoclonal antibody J591 conjugated to chelator desferrioxamine B 1
DFO-MSTP2109A (89Zr) Desferrioxamine - DFO-MSTP2109A is an antibody that works against STEAP1 - found on the surface of prostate cancer cells 1
DHT (18F)a (5S,8R,9S,10S,13S,14S,17S)-17-hydroxy-10,13-dimethyl-1,2,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-one 3
DOTA-Bombesin (68Ga) 68Ga-DOTA-Bombesin is a gallium-68-labeled gastrin-releasing peptide receptor (GRPr) antagonist. DOTA is [4,7,10-Tris-(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl]-acetyl. 1
DOTATET (68Ga) 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (also known as DOTA) 1
FAZA (18F) Nitroimidazole nucleoside analogue 1-(5-fluoro-5-deoxy-α-D-arabinofuranosyl)-2-nitroimidazole (FAZA) 2
FDG (18F)a 2-Deoxy-2-[18F]fluoroglucose 15
FLT (18F) 1-[(2R,4S,5R)-4-fluoro-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione 1
Fluciclovine (18F) Anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid 13
Fluciclovine (NOS) Anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid 1
Fluorocholine (18F) Fluoromethyl-(2-hydroxyethyl)-dimethylazanium;chloride 1
FMAU (18F) 2′-deoxy-2′-[18F]fluoro-5-methyl-1-beta-D-arabinofuranosyluracil (fluorine F 18 d-FMAU [18F-FMAU]), 3
MeAIB (NOS)a 2-methyl-2-(methylamino)propanoic acid 1
Methionine (11C)a (2S)-2-amino-4-methylsulfanylbutanoic acid 3
MISO (18F) 1-methoxy-3-(2-nitroimidazol-1-yl)propan-2-ol 1
NaF (18F)a Sodium;fluoride 20
NODAGA-MJ9 (Ga-68)a 1,4,7-triazacyclononane,1-glutaric acid-4,7 acetic acid (NODAGA) 1
NOTA-BBN-RGD (68Ga) 1,4,7-triazacyclononanetriacetic acid (NOTA), Arg-Gly-Asp (RGD) and bombesin (BBN) 1
P15–041 (68Ga) Unknown 1
PACAP (64Cu) Pituitary adenylate cyclase-activating peptide 2
Peripheral Benzodiazepine Receptor-28 (11C) Peripheral Benzodiazepine Receptor-28 1
PSMA DCFPyL (18F)a N-[N-[(S)-1,3-dicarboxypropyl]carbamoyl]-4-[18F]fluorobenzyl-L-cysteine ([18F]DCFBC) 21
PSMA (68Ga) Glutamate carboxypeptidase II, also known as N-acetyl-L-aspartyl-L-glutamate peptidase I 15
PSMA (89Zr) Glutamate carboxypeptidase II, also known as N-acetyl-L-aspartyl-L-glutamate peptidase I 2
PSMA CTT 1057 (NOS) Cancer Targeted Technology (CTT), a privately held Seattle-based biotechnology firm that will develop the agent, CTT1057. CTT1057 is a small molecule that homes in and binds irreversibly to prostate specific membrane antigen (PSMA) 1
PSMA DCFBC (18F) (N-[N-[(S)-1,3-dicarboxypropyl]carbamoyl]-4-F-fluorobenzyl-L-cysteine) (F-DCFBC) 4
PSMA Df-IAB2M (89Zr) Zr-89-desferrioxamine-IAB2M 1
RM2 (68Ga) 68Ga-RM2 stands for Galium-68 labeled DOTA-4-amino-1-carboxymethylpiperidine-D-Phe-Gln-Trp-Ala-Val-Gly-His-Sta-Leu-NH2 3
Sodium Fluoride (18F) Sodium Fluoride 1
uPAR NOTA (68Ga) Urokinase Plasminogen Activator Receptor 1
  1. aAgent was an optional or was compared to other agent in more than one trial